IDEMIA Awarded iBeta Certification for its Biometric Liveness Detection Solution
11.2.2020 17:31:00 EET | Business Wire | Press release
IDEMIA, the global leader in Augmented Identity, has announced that its liveness detection technology has been awarded Level 1 and Level 2 certification by iBeta, an independent third-party tester, in accordance with the ISO/IEC 30107-3 standards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005642/en/
(Photo: Business Wire)
Testing was conducted by independent quality assurance provider, iBeta, and completed in December 2019. The testing method simulated the enrollment of a user in a biometric authentication system, where legitimate users consented to photos and videos of their likeness being used in attempts to spoof the system (Level 1 testing), and also the use of more sophisticated artefacts like silicone, latex, and plastic masks (Level 2 testing).
The testers were not able to gain access to the system using any of the presentation attacks, meaning that IDEMIA’s liveness detection technology achieved an attack presentation classification error rate (APCER) of 0%.
IDEMIA’s SmartBio® and WebBioServer® SDKs both leverage the liveness detection technology, which enables clients to offer multi-channel identity verification solutions via Android and iOS mobile apps, or through web browsers on either desktop or mobile devices.
Increasingly, banks, mobile operators, and other service providers are under pressure to offer their customers a remote, digital onboarding journey. The mass adoption of mobile devices with biometric sensors, combined with widespread broadband coverage worldwide, make this transformation possible.
However, remote onboarding presents an opportunity for fraudsters to open an account using a presentation attack, which is when spoofed biometric information is presented to a biometric sensor. Common presentation attacks include a fake image or video of a legitimate customer, fake silicon or gelatin masks, and fake fingerprints.
Presentation attack detection (PAD) is vitally important for service providers that want to secure their digital onboarding processes while reducing the impact of fraud. PAD also helps service providers comply with anti-money laundering (AML) and counter-terrorism financing (CTF) regulations, which may result in hefty penalties from regulators should their processes be deemed inadequate for accurately combatting fraud.
To date, IDEMIA is one of just two companies worldwide to have achieved Level 2 Liveness Detection certification.
“At IDEMIA, we pride ourselves in our ability to create cutting-edge biometric solutions capable of streamlining a user’s digital journey and combatting fraud,” said Muzaffar Khokhar, Executive Vice President, Digital Business Unit, IDEMIA. “This independent accreditation proves our expertise, and will enable us to provide a more complete portfolio of onboarding and anti-fraud solutions for our clients across the globe.”
IDEMIA’s liveness detection technology is available through the SmartBio® and WebBioServer® SDKs, and is part of the company’s innovative digital identity platform. The platform is a powerful solution for enterprises and service providers to identify, manage, and authenticate digital identities in a secure, trusted, and convenient way.
iBeta is the only NIST NVLAP accredited biometrics testing lab (NVLAP testing Lab Code 200962-0). iBeta developed a quality management system and biometrics test procedures that are independently audited by NVLAP (National Voluntary Laboratory Accreditation Program) in a comprehensive technical evaluation in accordance with the recognized International Standard ISO/IEC 17025:2017.
View the IDEMIA PAD Level 1 Confirmation Letter (PDF)
View the IDEMIA PAD Level 2 Confirmation Letter (PDF)
For more information on IDEMIA’s digital identity platform and other digital identity technology, visit https://www.idemia.com/digital-identity-enterprises
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 13,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005642/en/
Contact information
Press
PR Agency: Havas Paris
Irina Pungaru
+33 6 13 02 34 76
idemia@havas.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
